Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 4/20 | 0.73 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.70 |
| ▸ | AR | P10275 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12384444 | 1.00 | SRD5A2 (0.73) | SRD5A2SRD5A1AR | |
| SCHEMBL12423998 | 1.00 | SRD5A2 (0.73) | SRD5A2SRD5A1AR | |
| SCHEMBL950691 | 1.00 | SRD5A2 (0.73) | SRD5A2SRD5A1AR | |
| SCHEMBL5907001 | 1.00 | SRD5A2 (0.73) | SRD5A2SRD5A1AR | |
| SCHEMBL13844000 | 1.00 | SRD5A2 (0.73) | SRD5A2SRD5A1AR | |
| SCHEMBL9150743 | 1.00 | SRD5A2 (0.73) | SRD5A2SRD5A1AR | |
| SCHEMBL14477867 | 1.00 | SRD5A2 (0.73) | SRD5A2SRD5A1AR | |
| SCHEMBL14397354 | 1.00 | SRD5A2 (0.73) | SRD5A2SRD5A1AR | |
| SCHEMBL28559933 | 0.90 | SRD5A2 (0.73) | SRD5A2SRD5A1AR | |
| SCHEMBL14477862 | 0.90 | SRD5A2 (0.73) | SRD5A2SRD5A1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059692-A1 | Process for the preparation of 17beta-N-[2,5-bis(trifluoromethyl)phenyl] carbamoyl-4-aza-5-alpha-androst-1-en-3-one | DR. REDDY'S LABORATORIES LIMITED | 2005-03-17 | — | — | US | claimed |
| EP-0298652-B1 | Dehydrogenation process and intermediates | MERCK & CO INC (US) | 1995-01-18 | — | — | EP | claimed |
| US-5084574-A | Reacting a 3-oxo-4-azasteroid with a silyating agent and quinone to form a double bond at the #1 ring position | MERCK & CO., INC. (US) | 1992-01-28 | — | — | US | claimed |
| EP-0298652-A2 | Dehydrogenation process and intermediates | MERCK & CO. INC. (US) | 1989-01-11 | — | — | EP | claimed |
| WO-2013001322-A1 | PROCESS FOR THE SYNTHESIS OF (5α,17β)-N-[(2,5-BIS(TRIFLUOROMETHYL)-PHENYL]-3-OXO-4-AZA-5-ANDROST-1-ENE-17-CARBOXAMIDE | RICHTER GEDEON NYRT. (HU) | 2013-01-03 | — | — | WO | disclosed |
| WO-2013001322-A1 | PROCESS FOR THE SYNTHESIS OF (5α,17β)-N-[(2,5-BIS(TRIFLUOROMETHYL)-PHENYL]-3-OXO-4-AZA-5-ANDROST-1-ENE-17-CARBOXAMIDE | RICHTER GEDEON NYRT. (HU) | 2013-01-03 | — | — | WO | disclosed |
| US-7872135-B2 | Method for introducing a 1,2-double bond into 3-oxo-4-azasteroid compounds | SIEGFRIED LTD. (CH) | 2011-01-18 | — | — | US | disclosed |
| US-7531658-B2 | Reacting 17-carboxylic acid-3-oxo-4-azasteroid with carbonyl- or sulfinyl-diimidazole and amidating the product with an amime in the presence of a heterocyclic hydroxyl activator; avoids the use of expensive and moisture sensitive organomagnesium halide; preparing Finasteride and Dutasteride | APOTEX PHARMACHEM INC. (CA) | 2009-05-12 | — | — | US | disclosed |
| WO-2008101308-A1 | PROCESS FOR THE PREPARATION OF 17-N-SUBSTITUTED-CARBAMOYL-4-AZA-ANDROST-1 -EN-3-ONES | APOTEX PHARMACHEM INC. (CA) | 2008-08-28 | — | — | WO | disclosed |
| US-20070173523-A1 | Process for the preparation of 17-N-substituted-carbamoyl-4-aza-androst-1-en-3-ones | APOTEX PHARMACHEM INC. (CA) | 2007-07-26 | — | — | US | disclosed |
| EP-1539703-A4 | METHOD FOR THE SELECTIVE PREPARATION OF 3-OXO-4-AZA-5A-ANDROSTANE COMPOUND | HANMI PHARM IND CO LTD (KR) | 2007-02-21 | — | — | EP | disclosed |
| US-7164022-B2 | Process for the preparation of pure Finasteride | AUROBINDO PHARMA LTD. (IN) | 2007-01-16 | — | — | US | disclosed |
| EP-0414490-A2 | 17 Beta-acyl-4-aza-5 alpha-androst-1-ene-3-one as 5 alpha-reductase inhibitors | MERCK & CO. INC. (US) | 1991-02-27 | — | — | EP | disclosed |
| EP-0414491-A2 | 17 Beta-acyl-4-aza-5 alpha-androst-1-ene-3-ones as 5 alpha-reductase inhibitors | MERCK & CO. INC. (US) | 1991-02-27 | — | — | EP | disclosed |
| US-4859681-A | 17 α-Acyl-4-aza-5a-androst-1-en-3-ones as 5 alpha-reductase inhibitors | MERCK & CO., INC. (US) | 1989-08-22 | — | — | US | disclosed |
| EP-0298652-A2 | Dehydrogenation process and intermediates | MERCK & CO. INC. (US) | 1989-01-11 | — | — | EP | disclosed |
| EP-0285383-A2 | Treatment of prostatic carcinoma with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones | MERCK & CO. INC. (US) | 1988-10-05 | — | — | EP | disclosed |
| EP-0285382-A2 | Treatment of androgenic alopecia with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones | MERCK & CO. INC. (US) | 1988-10-05 | — | — | EP | disclosed |
| EP-0271219-A1 | Topical pharmaceutical composition containing 17-beta-methoxycarbonyl-4-methyl-4-aza-5-alpha-androst-1-en-3-one | MERCK & CO. INC. (US) | 1988-06-15 | — | — | EP | disclosed |
| EP-0155096-A2 | 17 Beta-Substituted-4-aza-5-alpha-androstenones and their use as 5-alpha-reductase inhibitors | MERCK & CO. INC. (US) | 1985-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173523-A1 | Process for the preparation of 17-N-substituted-carbamoyl-4-aza-androst-1-en-3-ones | CYP17A1, CYP19A1, NR5A1 | SRD5A2 15/4885SRD5A1 16/4885AR 27/4885 |
| US-20050059692-A1 | Process for the preparation of 17beta-N-[2,5-bis(trifluoromethyl)phenyl] carbamoyl-4-aza-5-alpha-androst-1-en-3-one | NR5A1, CYP17A1, CYP19A1 | SRD5A2 8/4885SRD5A1 7/4885AR 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.